Immunoglobulin chimeric monomer-dimer hybrids
AssigneeSyntonix Pharmaceuticals, Inc.
InventorsRobert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
Life of this patent
Estimating the term…
Abstract
The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
Claims48
An isolated monomer-dimer hybrid immunoconjugate comprising
- X-La-F1:F2 or F2:F1-La-X
- wherein
- X is a single biologically active molecule,
- L is a linker,
- a is any integer or zero,
- :
- represents a chemical association,
- F1 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site and does not comprise a biologically active molecule, and
- F2 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site and does not comprise a biologically active molecule or immunoglobulin variable region.
An isolated monomer-dimer hybrid immunoconjugate of the formula
- X-La-F1:F2-T or T-F2:F1-La-X
- wherein
- X is a single biologically active molecule,
- L is a linker,
- a is any integer or zero,
- T is a molecule having a molecular weight less than 2 kD,
- :
- represents a chemical association,
- F1 is an immunoglobulin constant region or portion thereof comprising an FcRn binding site, and
- F2 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site.
An isolated monomer-dimer hybrid immunoconjugate of the formula
- X-La-F1:F2 or F2:F1-La-X
- wherein
- X is erythropoietin,
- L is a linker,
- a is any integer or zero,
- :
- represents a chemical association,
- F1 is an immunoglobulin constant region or portion thereof comprising an FcRn binding site;
- and
- F2 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site.
An isolated monomer-dimer hybrid immunoconjugate of the formula
- X-La-F1:F2 or F2:F1-La-X
- wherein
- X is IFNβ,
- L is a linker,
- a is any integer or zero,
- :
- represents a chemical association,
- F1 is an immunoglobulin constant region or portion thereof comprising an FcRn binding site;
- and
- F2 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site.
An isolated monomer-dimer hybrid immunoconjugate of the formula
- X-La-F1:F2 or F2:F1-La-X
- wherein
- X is Factor IX,
- L is a linker,
- a is any integer or zero,
- :
- represents a chemical association,
- F1 is an immunoglobulin constant region or portion thereof comprising an FcRn binding site;
- and
- F2 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site.
Dependencies are inferred from the claim text.